TrialArthritis research & therapy2022

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.

Martin Bergman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.